PHARMAVOX: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMAVOX
Largest movements
- Tangible fixed assets -€439,747
down €439,747 (-4.0%), from €10.9m to €10.5m
of which Land and buildings: -€434,777
- Cash -€410,742
down €410,742 (-80.5%), from €510,510 to €99,768
mainly Other debts (-€928,126) and Net result for the year (-€323,574)
- Receivables within one year -€333,701
down €333,701 (-99.9%), from €334,118 to €417
of which Trade receivables: -€325,260
- Current investments -€149,682
down €149,682 (-100.0%), from €149,682 to €0
- Stocks and contracts -€139,500
down €139,500 (-16.6%), from €839,500 to €700,000
- Other debts -€928,126
down €928,126 (-39.2%), from €2.4m to €1.4m
- Profit (loss) carried forward -€323,574
down €323,574 (-14.3%), from -€2.3m to -€2.6m
- Debts after one year -€212,024
down €212,024 (-7.2%), from €2.9m to €2.7m
of which Financial debts: -€217,200
- Write-downs +€139,500
new in 2025: €139,500
- Financial income +€102,968
up €102,968 (+1215.7%), from €8,470 to €111,438
- Gross operating margin -€76,610
down €76,610 (-17.8%), from €429,765 to €353,155
- Financial charges -€20,611
down €20,611 (-13.2%), from €156,709 to €136,098
- Other operating charges +€9,094
up €9,094 (+15.6%), from €58,315 to €67,408
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €12,734,090 | €11,260,152 | -€1.5m | -11.6% |
| Fixed assets | 21/28 | €10,896,924 | €10,457,177 | -€439,747 | -4.0% |
| Tangible fixed assets | 22/27 | €10,896,799 | €10,457,052 | -€439,747 | -4.0% |
| Land and buildings | 22 | €10,836,892 | €10,402,115 | -€434,777 | -4.0% |
| Plant, machinery and equipment | 23 | - | €2,800 | +€2,800 | |
| Furniture and vehicles | 24 | €5,335 | €3,416 | -€1,919 | -36.0% |
| Other tangible fixed assets | 26 | €54,573 | €48,722 | -€5,851 | -10.7% |
| Financial fixed assets | 28 | €125 | €125 | = | 0.0% |
| Current assets | 29/58 | €1,837,166 | €802,975 | -€1.0m | -56.3% |
| Stocks and contracts in progress | 3 | €839,500 | €700,000 | -€139,500 | -16.6% |
| Stocks | 30/36 | €839,500 | €700,000 | -€139,500 | -16.6% |
| Amounts receivable within one year | 40/41 | €334,118 | €417 | -€333,701 | -99.9% |
| Trade receivables | 40 | €325,260 | €0 | -€325,260 | -100.0% |
| Other amounts receivable | 41 | €8,858 | €417 | -€8,441 | -95.3% |
| Current investments | 50/53 | €149,682 | €0 | -€149,682 | -100.0% |
| Cash at bank and in hand | 54/58 | €510,510 | €99,768 | -€410,742 | -80.5% |
| Deferred charges and accrued income | 490/1 | €3,355 | €2,789 | -€566 | -16.9% |
| Total equity and liabilities | 10/49 | €12,734,090 | €11,260,152 | -€1.5m | -11.6% |
| Equity | 10/15 | €7,204,285 | €6,880,711 | -€323,574 | -4.5% |
| Contributions | 10/11 | €9,210,000 | €9,210,000 | = | 0.0% |
| Reserves | 13 | €264,056 | €264,056 | = | 0.0% |
| Non-distributable reserves | 130/1 | €264,056 | €264,056 | = | 0.0% |
| Reserves not available under the articles | 1311 | €264,056 | €264,056 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€2,269,771 | -€2,593,345 | -€323,574 | -14.3% |
| Amounts payable | 17/49 | €5,529,805 | €4,379,441 | -€1.2m | -20.8% |
| Amounts payable after more than one year | 17 | €2,925,103 | €2,713,079 | -€212,024 | -7.2% |
| Financial debts | 170/4 | €2,914,000 | €2,696,800 | -€217,200 | -7.5% |
| Other amounts payable | 178/9 | €11,103 | €16,279 | +€5,176 | +46.6% |
| Amounts payable within one year | 42/48 | €2,598,678 | €1,658,133 | -€940,546 | -36.2% |
| Current portion of amounts payable after more than one year | 42 | €217,200 | €217,200 | = | 0.0% |
| Trade debts | 44 | €14,576 | €3,038 | -€11,538 | -79.2% |
| Suppliers | 440/4 | €14,576 | €3,038 | -€11,538 | -79.2% |
| Taxes, remuneration and social security | 45 | €1,365 | €483 | -€882 | -64.6% |
| Taxes | 450/3 | €1,365 | €483 | -€882 | -64.6% |
| Other amounts payable | 47/48 | €2,365,537 | €1,437,412 | -€928,126 | -39.2% |
| Accrued charges and deferred income | 492/3 | €6,024 | €8,229 | +€2,206 | +36.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €443,570 | €445,160 | +€1,590 | +0.4% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | - | €139,500 | +€139,500 | |
| Other operating charges | 640/8 | €58,315 | €67,408 | +€9,094 | +15.6% |
| Gross operating margin | 9900 | €429,765 | €353,155 | -€76,610 | -17.8% |
| Operating profit (loss) | 9901 | -€72,120 | -€298,914 | -€226,794 | -314.5% |
| Financial income | 75/76B | €8,470 | €111,438 | +€102,968 | +1215.7% |
| Recurring financial income | 75 | €8,470 | €111,438 | +€102,968 | +1215.7% |
| Financial charges | 65/66B | €156,709 | €136,098 | -€20,611 | -13.2% |
| Recurring financial charges | 65 | €156,709 | €136,098 | -€20,611 | -13.2% |
| Profit (loss) for the period before taxes | 9903 | -€220,359 | -€323,574 | -€103,215 | -46.8% |
| Profit (loss) for the period | 9904 | -€220,359 | -€323,574 | -€103,215 | -46.8% |
| Profit (loss) for the period to be appropriated | 9905 | -€220,359 | -€323,574 | -€103,215 | -46.8% |
Source: filed annual accounts (NBB), fiscal years ended 31 March 2024 and 31 March 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.